LX1032 is being developed in a product development collaboration with Symphony Capital Partners, L.P. and its co-investors.
Lexicon is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. Lexicon currently has development programs underway for such areas of major unmet medical need as irritable bowel syndrome, cognitive disorders, and autoimmune diseases. The company has used its proprietary gene knockout technology to discover more than 100 promising drug targets and create an extensive pipeline of clinical and preclinical programs in the therapeutic areas of diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders and ophthalmic disease. To advance the development and commercialization of its programs, Lexicon is working both independently and through collaborators including Bristol-Myers Squibb Company, Genentech, Inc. and N.V. Organon. For additional information about Lexicon and its programs, please visit http://www.lexpharma.com.
Safe Harbor Statement
This press release contains "forward-looking statements," including
statements relating to Lexicon's clinical development of LX1032 and the
potential therapeutic and commercial potential of LX1032. This press
release also contains forward-looking statements relating to Lexicon's
growth and future operating results, discovery and development of products,
|SOURCE Lexicon Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved